TG Therapeutics, Inc. (TGTX) Stock Score, Valuation & Financial Research
TG Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 65/100.
Quick answer for TGTX
TG Therapeutics, Inc. currently has a Wall Street Score of 65/100. The stored market price is $54. Its financial score is 60/100. Its valuation score is 93/100. These figures are a research snapshot, not a buy or sell recommendation.
What TG Therapeutics, Inc. does
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular
TGTX financial snapshot
- Wall Street Score:
- 65/100
- Current price:
- $54
- Market capitalization:
- $8.27B
- Revenue:
- $700.3M
- Net income:
- $461.9M
- Free cash flow:
- $-25.0M
- Cash:
- $442.2M
- Total debt:
- $753.6M
- EPS:
- 3.10
- P/E ratio:
- 17.4x
- Financial score:
- 60/100
- Valuation score:
- 93/100
- Revenue score:
- 60/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-25.0M, showing cash burn in the current stored period.
- The balance sheet shows $442.2M of cash versus $753.6M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 93/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 60/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TGTX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.